MCID: BLD039
MIFTS: 35

Bladder Adenocarcinoma

Categories: Cancer diseases, Nephrological diseases

Aliases & Classifications for Bladder Adenocarcinoma

MalaCards integrated aliases for Bladder Adenocarcinoma:

Name: Bladder Adenocarcinoma 12 14 69
Bladder Adenocarcinoma, Not Otherwise Specified 12
Adenocarcinoma of the Urinary Bladder 12
Adenocarcinoma of Bladder 12
Adenocarcinoma Bladder 52

Classifications:



External Ids:

Disease Ontology 12 DOID:3711
NCIt 47 C39836 C4032
SNOMED-CT 64 255110003
UMLS 69 C0279682

Summaries for Bladder Adenocarcinoma

Disease Ontology : 12 A bladder carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Bladder Adenocarcinoma, also known as bladder adenocarcinoma, not otherwise specified, is related to pelvic lipomatosis and bladder clear cell adenocarcinoma, and has symptoms including dysuria An important gene associated with Bladder Adenocarcinoma is CDX2 (Caudal Type Homeobox 2), and among its related pathways/superpathways are Primary Focal Segmental Glomerulosclerosis FSGS and Preimplantation Embryo. The drugs Fesoterodine and Neurotransmitter Agents have been mentioned in the context of this disorder. Affiliated tissues include prostate, kidney and liver.

Related Diseases for Bladder Adenocarcinoma

Diseases related to Bladder Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 82)
id Related Disease Score Top Affiliating Genes
1 pelvic lipomatosis 10.9
2 bladder clear cell adenocarcinoma 10.9
3 bladder signet ring cell adenocarcinoma 10.9
4 boylan dew greco syndrome 10.4 MKI67 PCNA
5 orbital lymphoma 10.4 MKI67 PCNA
6 pediatric meningioma 10.4 MKI67 PCNA
7 levy-yeboa syndrome 10.4 MKI67 PCNA
8 hip subluxation 10.3 CDX2 MKI67
9 laryngeal adenoid cystic carcinoma 10.3 MKI67 PCNA
10 adenocarcinoma 10.3
11 pineal region meningioma 10.3 CDX2 GATA3
12 myoepithelial carcinoma 10.2 KRT20 MKI67
13 ovarian mucinous adenocarcinoma 10.2 KRT20 PCNA
14 sensory system cancer 10.2 CDX2 KRT20
15 lung occult small cell carcinoma 10.2 CDX2 KRT20
16 fibroepithelial polyp of urethra 10.2 CDX2 KRT20
17 rhinosporidiosis 10.2 CDX2 KRT20
18 chronic neutrophilic leukemia 10.2 CDX2 KRT20
19 breast mucinous cystadenocarcinoma 10.2 CDX2 KRT20
20 childhood teratoma of the ovary 10.2 CDX2 KRT20
21 intrahepatic cholangiocarcinoma 10.2 CDX2 KRT20
22 giant cell tumor 10.2 CDX2 KRT20
23 myotonia congenita 10.2 CDX2 KRT20
24 ovarian melanoma 10.2 CDX2 KRT20
25 neuroendocrine tumor 10.2 CDX2 KRT20
26 tabes dorsalis 10.2 CDX2 KRT20
27 stricture or kinking of ureter 10.2 CDX2 KRT20
28 anemia of prematurity 10.2 CDX2 KRT20
29 uterine corpus adenofibroma 10.1 CDX2 KRT20
30 mesenchymoma 10.1 CDX2 KRT20
31 wissler's syndrome 10.1 CDX2 KRT20
32 human t-cell leukemia virus type 1 10.1 CDX2 KRT20
33 spastic ataxia 3 10.1 CDX2 KRT20
34 migraine with aura 10.1 CDX2 KRT20
35 childhood ovarian endodermal sinus tumor 10.1 CDX2 KRT20
36 cavernous sinus thrombosis 10.1 CDX2 KRT20
37 pacinian tumor 10.1 CDX2 KRT20
38 postpoliomyelitis syndrome 10.1 CDX2 KRT20
39 pancreatic signet ring cell adenocarcinoma 10.1 CDX2 KRT20
40 breast mucinous carcinoma 10.1 CDX2 KRT20
41 fasciolopsiasis 10.1 KRT20 PCNA
42 optic papillitis 10.1 CDX2 KRT20
43 microcystic meningioma 10.1 CDX2 KRT20
44 nominal aphasia 10.1 MKI67 PCNA
45 cecum adenocarcinoma 10.1 CDX2 KRT20
46 perivascular epithelioid cell tumor 10.0 GATA3 KRT20
47 paralytic ileus 10.0 CDX2 KRT20
48 fallopian tube mucinous tumor 10.0 CDX2 KRT20
49 prostate transitional cell carcinoma 10.0 GATA3 KRT20
50 esophagus sarcoma 10.0 KLK3 PCNA

Graphical network of the top 20 diseases related to Bladder Adenocarcinoma:



Diseases related to Bladder Adenocarcinoma

Symptoms & Phenotypes for Bladder Adenocarcinoma

UMLS symptoms related to Bladder Adenocarcinoma:


dysuria

Drugs & Therapeutics for Bladder Adenocarcinoma

Drugs for Bladder Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 143)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fesoterodine Approved Phase 4 286930-02-7, 286930-03-8 6918558
2 Neurotransmitter Agents Phase 4
3 Cholinergic Agents Phase 4
4 Cholinergic Antagonists Phase 4
5 Muscarinic Antagonists Phase 4
6
Epirubicin Approved Phase 3 56420-45-2 41867
7
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
8
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
9
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
10
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
11
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
12
Oxaliplatin Approved, Investigational Phase 3,Phase 1 61825-94-3 5310940 9887054 43805 6857599
13
BCG vaccine Investigational Phase 3
14 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
15 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
16 Alkylating Agents Phase 3,Phase 2
17 Anti-Bacterial Agents Phase 3,Phase 2
18 Antibiotics, Antitubercular Phase 3,Phase 2
19 Anti-Infective Agents Phase 3,Phase 2,Phase 1
20 Antiviral Agents Phase 3,Phase 2,Phase 1
21 Interferon-alpha Phase 3
22 interferons Phase 3
23 Mitomycins Phase 3,Phase 2
24 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
25 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
26 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
27 Vaccines Phase 3,Phase 1
28 Antimetabolites Phase 3,Phase 2,Phase 1
29 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
30 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
31 Adjuvants, Anesthesia Phase 3
32 Analgesics Phase 3
33 Analgesics, Opioid Phase 3
34 Anesthetics Phase 3
35 Anesthetics, General Phase 3
36 Anesthetics, Intravenous Phase 3
37 Central Nervous System Depressants Phase 3
38 Liver Extracts Phase 3,Phase 1
39 Narcotics Phase 3
40 Peripheral Nervous System Agents Phase 3
41 Androgens Phase 3,Phase 1,Phase 2
42 Hormone Antagonists Phase 3
43 Hormones Phase 3,Phase 1,Phase 2
44 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
45 Cola Nutraceutical Phase 3,Phase 1,Phase 2
46
Ifosfamide Approved Phase 2 3778-73-2 3690
47
Mechlorethamine Approved Phase 2 51-75-2 4033
48
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
49
Bevacizumab Approved, Investigational Phase 2 216974-75-3
50
Amifostine Approved, Investigational Phase 2 20537-88-6 2141

Interventional clinical trials:

(show top 50) (show all 91)

id Name Status NCT ID Phase Drugs
1 A Study of the Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Laparoscopic Prostatectomy Active, not recruiting NCT01661166 Phase 4 Fesoterodine
2 Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer Unknown status NCT01094964 Phase 3 epirubicin hydrochloride;mitomycin C
3 Randomized Trial on Robotic Assisted Resection for Rectal Cancer Unknown status NCT01130233 Phase 3
4 Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer Completed NCT00024349 Phase 3 fluorouracil;mitomycin C
5 Image Guided Radiation Therapy For Prostate Cancer Completed NCT00433706 Phase 3
6 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
7 Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer Recruiting NCT02170090 Phase 3 Gemcitabine;Cisplatin;Capecitabine
8 Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients Recruiting NCT02303327 Phase 3 Androgen deprivation therapy
9 Study of GEMOX(Gemcitabine/Oxaliplatin) Versus XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma Recruiting NCT01470443 Phase 3 Oxaliplatin;Oxaliplatin
10 Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the Prostate Active, not recruiting NCT01444820 Phase 3
11 Radiotherapy - Adjuvant Versus Early Salvage Active, not recruiting NCT00860652 Phase 3
12 Standard Surgery or Minimal-Access Surgery in Treating Patients With Bladder Cancer Unknown status NCT01196403 Phase 2
13 VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium Completed NCT00407485 Phase 2
14 Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract Completed NCT00002914 Phase 2 piritrexim
15 Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer Completed NCT00002684 Phase 2 cisplatin;ifosfamide;paclitaxel
16 Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract Completed NCT00006026 Phase 2 rubitecan
17 A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts Completed NCT01007552 Phase 2 Gemcitabine, Capecitabine and Bevacizumab
18 Trial Evaluating the Efficacy of Laying a Biliary Stent for Producing a Heavy Chemotherapy in Unresectable Pancreatic Adenocarcinomas Completed NCT02487836 Phase 2
19 Prophylactic Urethral Stenting With Memokath After Prostate Implantation for Prostate Adenocarcinoma Completed NCT00252941 Phase 1, Phase 2
20 Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer Completed NCT00075504 Phase 2 triapine;gemcitabine
21 Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer Completed NCT00002602 Phase 1, Phase 2
22 Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery Completed NCT00003744 Phase 2 gemcitabine
23 Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types Completed NCT00633789 Phase 2 brivanib;Placebo
24 High-dose ICE With Amifostine Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
25 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2 docetaxel
26 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
27 Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology Recruiting NCT03092518 Phase 2 Cisplatin;Mitomycin C;Sodium Thiosulfate
28 Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium Recruiting NCT00756639 Phase 2
29 Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers Recruiting NCT01631552 Phase 1, Phase 2 IMMU-132
30 Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers Recruiting NCT02141490 Phase 2 Ferumoxytol
31 A Study to Evaluate the Efficacy, and Safety of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Urothelial Bladder Cancer (UBC) or Pancreas/Cholangio Cancer (Kameleon Study Recruiting NCT02999672 Phase 2 Trastuzumab Emtansine
32 Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometrial Cancer. ICORG 09-06 Recruiting NCT01164150 Phase 2
33 Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting NCT03170960 Phase 1, Phase 2 cabozantinib;atezolizumab;cabozantinib
34 A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors Recruiting NCT02886897 Phase 1, Phase 2
35 Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma Recruiting NCT02631590 Phase 2 Cisplatin;Gemcitabine;Copanlisib
36 A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers Recruiting NCT03115801 Phase 2 Nivolumab;Atezolizumab
37 A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers Recruiting NCT02923934 Phase 2 Ipilimumab;Nivolumab
38 Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant Active, not recruiting NCT00082706 Phase 2 5-Fluorouracil (5-FU);Leucovorin;Cisplatin;Gemcitabine
39 Study of Tremelimumab in Patients With Advanced Solid Tumors Active, not recruiting NCT02527434 Phase 2
40 Surgery Combined With Intensity Modulated Radiation Therapy - Image-Guided Radiation Therapy (IMRT-IGRT) in Locally-advanced Prostate Cancers Active, not recruiting NCT01148069 Phase 2
41 Two StereoTactic Ablative Adaptive Radiotherapy Treatments for Localized Prostate Cancer Active, not recruiting NCT02031328 Phase 1, Phase 2
42 A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors Active, not recruiting NCT01928394 Phase 1, Phase 2 Cobimetinib
43 Cabozantinib for Advanced Urothelial Cancer Active, not recruiting NCT01688999 Phase 2 Cabozantinib
44 Hypofractionated Radiotherapy Versus Stereotactic Irradiation With Hyaluronic Acid Active, not recruiting NCT02361515 Phase 2
45 Can the Rectum be Saved by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer? Not yet recruiting NCT02945566 Phase 2 Long course concurrent chemoradiation
46 Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium Terminated NCT00112905 Phase 2 sorafenib tosylate
47 S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract Terminated NCT00022633 Phase 2 gemcitabine hydrochloride;paclitaxel
48 Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists Terminated NCT00447226 Phase 2 Oral lapatinib tablets or placebo tablets
49 3-Dimensional Conformal Radiation Therapy in Treating Patients With Bladder Cancer Who Have Undergone Transurethral Resection of the Bladder Unknown status NCT01124682 Phase 1
50 MRI-Guided Radiation Therapy in Treating Patients Who Have Undergone Surgery to Remove the Prostate Unknown status NCT01028885 Phase 1

Search NIH Clinical Center for Bladder Adenocarcinoma

Genetic Tests for Bladder Adenocarcinoma

Anatomical Context for Bladder Adenocarcinoma

MalaCards organs/tissues related to Bladder Adenocarcinoma:

39
Prostate, Kidney, Liver, Lung, Endothelial, Testes, Salivary Gland

Publications for Bladder Adenocarcinoma

Articles related to Bladder Adenocarcinoma:

(show all 35)
id Title Authors Year
1
Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma. ( 28548125 )
2017
2
Bladder Adenocarcinoma: A Persisting Diagnostic Dilemma. ( 28511402 )
2017
3
Urinary Bladder Adenocarcinoma Metastatic to the Abdominal Wall: Report of a Case with Cytohistologic Correlation. ( 27006847 )
2016
4
Effect of tumor location on survival in urinary bladder adenocarcinoma: A population-based analysis. ( 27427223 )
2016
5
Anterior pelvic exenteration for exstrophic bladder adenocarcinoma: Case report and review. ( 27288750 )
2016
6
Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee. ( 27048257 )
2016
7
A novel treatment approach prolonging survival in an uncommon metastatic primary bladder adenocarcinoma. ( 26955660 )
2016
8
Mucinous Bladder Adenocarcinoma: Case Report and Literature Review. ( 26421206 )
2015
9
Gall bladder Adenocarcinoma in a Young Girl. ( 26139973 )
2015
10
Hepatobiliary and pancreatic: coexisting cancers: Hepatic neuroendocrine carcinomas with gall bladder adenocarcinoma. ( 25040620 )
2014
11
Bladder metastasis from lung adenocarcinoma: a difficult differential diagnosis with primary bladder adenocarcinoma. ( 24716732 )
2014
12
Complete Response of Primary Bladder Adenocarcinoma with the FOLFOX4 Regimen. ( 24281125 )
2013
13
[Bladder adenocarcinoma 41 years after augmentation enterocystoplasty for tuberculosis]. ( 23589601 )
2013
14
Co-occurrence of acanthosis nigricans and bladder adenocarcinoma - case report. ( 24596525 )
2013
15
KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas. ( 22804747 )
2012
16
Primary bladder adenocarcinoma versus metastatic colorectal adenocarcinoma: a persisting diagnostic challenge. ( 23121893 )
2012
17
Sweet's syndrome as the presenting manifestation of gall bladder adenocarcinoma. ( 23076693 )
2012
18
Coexisting metastatic choriocarcinoma and bladder adenocarcinoma of common germ cell origin. ( 22294067 )
2011
19
Decoy cells and malignant cells coexisting in the urine from a transplant recipient with BK virus nephropathy and bladder adenocarcinoma. ( 22081531 )
2011
20
Association of bladder adenocarcinoma and BK virus infection in a pancreatico-renal transplant recipient. ( 28657060 )
2010
21
Bladder adenocarcinoma following gastrocystoplasty. ( 20392671 )
2010
22
In vivo reflectance confocal microscopy for cutaneous metastasis of bladder adenocarcinoma. ( 19221283 )
2009
23
A case of relapsing secondary bladder adenocarcinoma after right colonic cancer. ( 18604226 )
2008
24
Giant T4 rectal carcinoma mimicking urinary bladder adenocarcinoma accurately diagnosed by immunohistochemistry and successfully treated with total pelvic exenteration: report of a case. ( 18307003 )
2008
25
Urinary bladder adenocarcinoma arising in a spina bifida patient. ( 18022132 )
2007
26
Leptomeningeal carcinomatosis from urinary bladder adenocarcinoma: a clinicopathological case study. ( 15822823 )
2005
27
Hepatocellular carcinoma and gall bladder adenocarcinoma: two primaries with no significant risk factors. ( 19861819 )
2003
28
Spontaneous resolution of bladder adenocarcinoma. ( 15160537 )
2003
29
The prognostic importance of the nucleolar organizer region (AgNOR), Ki-67 and proliferating cell nuclear antigen (PCNA) in primary nonurachal bladder adenocarcinoma. ( 11506474 )
2001
30
Bladder adenocarcinoma: 31 reported cases. ( 11718635 )
2001
31
Recurrent bladder adenocarcinoma in an ileal conduit stoma: a case report. ( 10510893 )
1999
32
Urine cytology of primary and secondary urinary bladder adenocarcinoma. ( 9915134 )
1998
33
Bladder adenocarcinoma during pregnancy: a case report. ( 8855078 )
1996
34
Adenocarcinoma in an ileal conduit: recurrence of bladder adenocarcinoma. ( 8389497 )
1993
35
Alpha-1-antitrypsin (AAT) deposits in gall bladder adenocarcinoma and liver in partial AAT deficiency (Pi SZ phenotype). ( 6983292 )
1982

Variations for Bladder Adenocarcinoma

Expression for Bladder Adenocarcinoma

Search GEO for disease gene expression data for Bladder Adenocarcinoma.

Pathways for Bladder Adenocarcinoma

Pathways related to Bladder Adenocarcinoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 10.82 MKI67 PCNA
2 10.4 CDX2 GATA3

GO Terms for Bladder Adenocarcinoma

Biological processes related to Bladder Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell differentiation GO:0045597 8.62 CDX2 GATA3

Sources for Bladder Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....